CAS 180916-16-9

Lasofoxifene

Description:

Lasofoxifene is a selective estrogen receptor modulator (SERM) that is primarily investigated for its potential use in treating osteoporosis and breast cancer. It exhibits tissue-selective estrogenic activity, meaning it can mimic estrogen in certain tissues while blocking its effects in others. This characteristic makes it particularly valuable in managing conditions related to estrogen deficiency, such as osteoporosis, without the associated risks of traditional hormone replacement therapies. Lasofoxifene has been shown to improve bone mineral density and reduce the risk of vertebral fractures in postmenopausal women. Additionally, it has demonstrated anti-estrogenic effects in breast tissue, which may contribute to its potential role in breast cancer prevention. The compound is known for its favorable pharmacokinetic profile, including oral bioavailability and a relatively long half-life, allowing for convenient dosing regimens. However, like all SERMs, it may have side effects, and its long-term safety profile is still under investigation. Overall, lasofoxifene represents a promising therapeutic option in the realm of hormone-related conditions.

Formula: C₂₈H₃₁NO₂

InChI: InChI=1/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1

InChI key: InChIKey=GXESHMAMLJKROZ-IAPPQJPRSA-N

SMILES: OC=1C=C2C([C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4)=CC1

Synonyms:

• (-)-cis-6(S)-Phenyl-5(R)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
• (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol
• (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]tetralin-2-ol
• (5R,6S)-6-phenyl-5-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
• (5R-cis)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol
• 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-
• 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R-cis)-
• Cp-336,156
• Lasofoxifene
• Lasofoxifene Base
• (5R,6S)-

2-NAPHTHALENOL, 5,6,7,8-TETRAHYDRO-6-PHENYL-5-[4-[2-(1-PYRROLIDINYL)ETHOXY]PHENYL]-, (5R,6S)-

CAS: 180916-16-9

Formula: C₂₈H₃₁NO₂

Purity: %

Color and Shape: Solid

Molecular weight: 413.5512

Ref: IN-DA0022GL

S07-2010

CAS: 180916-16-9

S07-2010

Purity: ≥98%

Molecular weight: 371.45g/mol

Ref: 54-BUP20707

Lasofoxifene

CAS: 180916-16-9

Formula: C₂₈H₃₁NO₂

Molecular weight: 413.56

Ref: 4Z-L-191

Lasofoxifene-d4

CAS: 180916-16-9

Formula: C₂₈H₂₇D₄NO₂

Molecular weight: 417.59

Ref: 4Z-L-192

Lasofoxifene

CAS: 180916-16-9

Lasofoxifene (CP-336156) is a selective oestrogen receptor modulator/antagonist that reduces serum IL-6 levels and inhibits joint inflammation and osteoporosis.

Formula: C₂₈H₃₁NO₂

Purity: 99.6%

Color and Shape: Solid

Molecular weight: 413.55

Ref: TM-T62119

Lasofoxifene

CAS: 180916-16-9

Applications A next-generation selective estrogen receptor modulator for treating disorders associated with increased bone turnover and osteopenia.
References Baumann, R., et al.: Biochem. Pharmacol., 55, 841 (1998), Ammann, P., et al.: Osteoporos Int., 10, 369 (1999), Alexandersen, P., et al.: J. Clin. Endocrinol. Metab., 86, 755 (2001), Bourrin, S., et al.: Bone, 30, 195 (2002), Buzdar, A., et al.: J. Clin. Oncol., 21, 1007 (2003),

Formula: C₂₈H₃₁NO₂

Color and Shape: Neat

Molecular weight: 413.55

Ref: TR-L176500